Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | G6PD | P11413 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.46 |
| ▸ | MAPT | P10636 | 5/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 5/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 4/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4860033 | 0.89 | G6PD (0.44) | G6PDMEN1KMT2AMAPK1KDM4E | |
| SCHEMBL4857002 | 0.88 | SQOR (0.45) | G6PDMEN1KMT2AMAPK1KDM4E | |
| SCHEMBL4863240 | 0.86 | MAPT (0.50) | G6PDMEN1KMT2AMAPK1KDM4E | |
| SCHEMBL2953222 | 0.86 | MAPT (0.50) | G6PDMEN1KMT2AMAPK1KDM4E | |
| SCHEMBL14223776 | 0.85 | G6PD (0.58) | G6PDMEN1KMT2AMAPK1KDM4E | |
| SCHEMBL4637042 | 0.84 | G6PD (0.57) | G6PDMEN1KMT2AMAPK1KDM4E | |
| SCHEMBL4862257 | 0.83 | ALDH1A1 (0.49) | G6PDMEN1KMT2AKDM4EMAPT | |
| SCHEMBL5818146 | 0.81 | G6PD (0.56) | G6PDMEN1KMT2AMAPK1KDM4E | |
| SCHEMBL4854645 | 0.81 | MEN1 (0.49) | G6PDMEN1KMT2AKDM4EMAPT | |
| SCHEMBL5818138 | 0.79 | G6PD (0.56) | G6PDMEN1KMT2AMAPK1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040259891-A1 | Novel pyrimidon derivatives | ORCHID CHEMICAL & PHARMACEUTICALS LIMITED (IN) | 2004-12-23 | — | — | US | claimed |
| US-7759350-B2 | Pyrimidine carboxamides | ORCHID RESEARCH LABORATORIES LTD. (IN) | 2010-07-20 | — | — | US | disclosed |
| US-7365069-B2 | Pyrimidone derivatives | BEXEL PHARMACEUTICALS INC. (US) | 2008-04-29 | — | — | US | disclosed |
| US-20070072876-A1 | Novel pyrimidine carboxamides | ORCHID RESEARCH LABORATORIES LTD. (IN) | 2007-03-29 | — | — | US | disclosed |
| US-20040259891-A1 | Novel pyrimidon derivatives | ORCHID CHEMICAL & PHARMACEUTICALS LIMITED (IN) | 2004-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072876-A1 | Novel pyrimidine carboxamides | UACA, SI, MYLK2 | G6PD 795/4885MEN1 1887/4885KMT2A 4280/4885 |
| US-20040259891-A1 | Novel pyrimidon derivatives | TYMS, TPMT, TYMP | G6PD 36/4885MEN1 917/4885KMT2A 4298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.